Integrating pharmacogenomic and pharmacometabolomic data towards personalized opioid therapies for cancer pain
Acronym
PHENOMENA
Location
Segrate
Start Date
2020
End Date
2026
Funder
AIRC
Partners
Fondazione IRCCS Istituto Nazionale dei Tumori, Milan (Italy)
Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milan (Italy)
Norwegian University of Science and Technology, Trondheim (Norway)
IBSBC-CNR, Segrate, MI (Italy)
This project focuses on improving pain management in oncology palliative care, where opioid therapy is often insufficient or causes adverse effects. The variability in opioid response among patients is not fully understood, but genetics is believed to play a key role. Previous pharmacogenetic studies identified gene variants linked to opioid response, yet results were inconsistent and lacked clinical applicability. Our team conducted the first genome-wide association study in cancer patients treated with opioids, highlighting the need for a broader “multi-omics” approach. Pharmacometabolomics, an emerging field studying metabolites and their influence on drug response, can complement pharmacogenomics to advance precision medicine. No metabolomic research has explored cancer patients receiving opioids. This project aims to integrate genomic and metabolomic data to discover biomarkers predicting opioid efficacy and toxicity, paving the way for personalized pain therapy in oncology.
Publications
Minnai F, Shkodra M, Noci S, Esposito M, Brunelli C, Pigni A, Zecca E, Skorpen F, Klepstad P, Kaasa S, Corli O, Pallotti MC, Maltoni MC, Caraceni AT, Colombo F. A genome-wide association study of European advanced cancer patients treated with opioids identifies regulatory variants on chromosome 20 associated with pain intensity. DOI: 10.1002/ejp.4764.
Minnai F, Shkodra M, Noci S, Brunelli C, Pigni A, Zecca E, Skorpen F, Klepstad P, Kaasa S, Corli O, Pallotti MC, Maltoni MC, Caraceni AT, Colombo F. Genomic Study in Opioid-Treated Cancer Patients Identifies Variants Associated With Nausea-Vomiting. DOI: https://doi.org/10.1016/j.jpainsymman.2024.10.033
To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behaviour or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Functional
Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes.The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.